Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA • Her2+ • NCI-CCC Breast Tumor Board Question
In what situations would you offer systemic therapy for HER2+ microinvasive invasive ductal carcinoma?
Answer from: Medical Oncologist at Academic Institution
I usually do not treat microinvasive HER2+ ductal cancer as most screen-detected cases still have a good prognosis and there is limited data for therapy benefit. A review by Padmore et al. (PMID 10717623) and a Chinese series (Si et al. Front Oncol 2020) suggested a higher risk of recurrence in youn...
Sign in or Register to read more